Immunotherapy that leverages HPV-specific immune responses for precancer lesions of cervical cancer
Cervical cancer and its precursor lesion, cervical intraepithelial neoplasia (CIN), are caused by high-risk human papillomavirus (HPV) viral infection and are highly susceptible to host immunity targeting of HPV viral proteins, which include both foreign antigens and cancer antigens expressed by tum...
Main Authors: | Osamu Kobayashi, Ayumi Taguchi, Takahiro Nakajima, Yuji Ikeda, Keisuke Saito, Kei Kawana |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2024-01-01
|
Series: | Taiwanese Journal of Obstetrics & Gynecology |
Subjects: | |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1028455923003005 |
Similar Items
-
A Placebo-Controlled, Double-Blind Randomized (Phase IIB) Trial of Oral Administration with HPV16 E7-Expressing <i>Lactobacillus</i>, GLBL101c, for the Treatment of Cervical Intraepithelial Neoplasia Grade 2 (CIN2)
by: Yuji Ikeda, et al.
Published: (2021-04-01) -
Micronutrients and prevention of cervical pre-cancer in HPV vaccinated women: a cross-sectional study
by: Chandrika J Piyathilake, et al.
Published: (2023-02-01) -
Women with a positive high-risk human papillomavirus (HPV) test remain at increased risk of HPV infection and cervical precancer ≥15 years later
by: Federica Inturrisi, et al.
Published: (2022-12-01) -
Prophylactic HPV vaccines
by: Mandić Aljoša
Published: (2009-01-01) -
Association between Cervical Microbiota and HPV: Could This Be the Key to Complete Cervical Cancer Eradication?
by: Eliano Cascardi, et al.
Published: (2022-07-01)